These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 35082402)

  • 1. Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
    Adamia S; Bhatt S; Wen K; Chyra Z; Fell GG; Tai YT; Pioso MS; Abiatari I; Letai A; Dorfman DM; Hideshima T; Anderson KC
    Leukemia; 2022 Apr; 36(4):1088-1101. PubMed ID: 35082402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological, preclinical and clinical aspects of the association between radiation therapy and CDK4/6 inhibitors].
    Beddok A; Porte B; Cottu P; Fourquet A; Kirova Y
    Cancer Radiother; 2023 May; 27(3):240-248. PubMed ID: 37080859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
    Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
    Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Kawamoto T; Shikama N; Imano N; Kubota H; Kosugi T; Sekii S; Harada H; Yamada K; Naoi Y; Miyazawa K; Hirano Y; Wada Y; Tonari A; Saito T; Uchida N; Araki N; Nakamura N
    Breast Cancer; 2023 Mar; 30(2):282-292. PubMed ID: 36528759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR
    Bardia A; Hurvitz SA; DeMichele A; Clark AS; Zelnak A; Yardley DA; Karuturi M; Sanft T; Blau S; Hart L; Ma C; Rugo HS; Purkayastha D; Moulder S
    Clin Cancer Res; 2021 Aug; 27(15):4177-4185. PubMed ID: 33722897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
    Schneeweiss A; Ettl J; Lüftner D; Beckmann MW; Belleville E; Fasching PA; Fehm TN; Geberth M; Häberle L; Hadji P; Hartkopf AD; Hielscher C; Huober J; Ruckhäberle E; Janni W; Kolberg HC; Kurbacher CM; Klein E; Lux MP; Müller V; Nabieva N; Overkamp F; Tesch H; Laakmann E; Taran FA; Seitz J; Thomssen C; Untch M; Wimberger P; Wuerstlein R; Volz B; Wallwiener D; Wallwiener M; Brucker SY
    Breast; 2020 Dec; 54():88-95. PubMed ID: 32956934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
    Takatsuka D; Sawaki M; Hattori M; Yoshimura A; Kotani H; Kataoka A; Horisawa N; Ozaki Y; Endo Y; Nozawa K; Iwata H
    Asia Pac J Clin Oncol; 2023 Oct; 19(5):e175-e182. PubMed ID: 36085411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
    Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
    Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study.
    Al-Rashdan A; Quirk S; Roumeliotis M; Abedin T; Amaro CP; Barbera L; Lupichuk S; Cao JQ
    Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):399-408. PubMed ID: 35870712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.
    Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
    Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Beddok A; Mouren V; Cottu P; Laki F; Fourquet A; Kirova Y
    Int J Cancer; 2023 Oct; 153(7):1386-1396. PubMed ID: 37381597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR
    Sammons S; Shastry M; Dent S; Anders C; Hamilton E
    Clin Breast Cancer; 2020 Feb; 20(1):1-11. PubMed ID: 31780379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
    Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
    Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of CK1ε potentiates the therapeutic efficacy of CDK4/6 inhibitor in breast cancer.
    Dang F; Nie L; Zhou J; Shimizu K; Chu C; Wu Z; Fassl A; Ke S; Wang Y; Zhang J; Zhang T; Tu Z; Inuzuka H; Sicinski P; Bass AJ; Wei W
    Nat Commun; 2021 Sep; 12(1):5386. PubMed ID: 34508104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.
    Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB
    Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials.
    Tian Q; Gao H; Zhou Y; Yang J
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.